Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer

@article{Sasaki2010FeasibilitySO,
  title={Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer},
  author={Takashi Sasaki and Hiroyuki Isayama and Yousuke Nakai and Suguru Mizuno and Keisuke Yamamoto and Hiroshi Yagioka and Yoko Yashima and Kazumichi Kawakubo and Hirofumi Kogure and Osamu Togawa and Saburo Matsubara and Naoki Sasahira and Kenji Hirano and Takeshi Tsujino and Minoru Tada and Masao Omata and Kazuhiko Koike},
  journal={Investigational New Drugs},
  year={2010},
  volume={29},
  pages={1488-1493}
}
Gemcitabine and cisplatin combination chemotherapy have been shown to have promising efficacy for the treatment of advanced biliary tract cancer (BTC) as a first-line chemotherapy. However, this treatment has not been approved for clinical practice in Japan. Oral fluoropyrimidines (e.g., S-1 and capecitabine) are also promising agents that are widely used with or without gemcitabine. Unfortunately, there is no standard chemotherapy for patients refractory to gemcitabine and oral… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Similar Papers

Loading similar papers…